Pharmaceutical Drug Development Annual Review - 2025
Summary
This report investigates the year 2025 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.Scope
This 50-page report gives important, expert insight you won’t find in any other source. 28 figures and tables throughout the report illustrate major points and trends in future pharmaceutical sales forecasts and company pipelines. This report is required reading for:- Investors that want to understand past trends impacting the biopharmaceutical industry as well as identifying companies to invest in
- Companies that are interested in entering the biopharmaceutical space and where best to focus on
- Large pharma companies with investment groups or BD teams looking to see which companies lead the industry in the past and how they led
- Small and medium pharma who want to focus their drug portfolio on future trends and are looking for partnership opportunities
Reasons to Buy
- Insights on how drug development in 2025 may impact future approvals
- Insights on how drug approvals in 2025 may impact future drug development and approval trends
- Sales and regulatory-based insights into 2025 covering various drugs and companies
Table of Contents
- Executive Summary
- 2025 Pipeline Development
- Top Therapy Areas - 2024 vs 2025
- Top Indications - 2024 vs 2025
- Top Molecule Types - 2024 vs 2025
- Top Targets - 2024 vs 2025
- Top RoAs - 2024 vs 2025
- 2025 Approvals
- FDA, EMA, PMDA Approval Trends, 2021-25
- Review Designation-Linked Approvals, 2021-25
- Manufacturer Average Drug Price Changes
- HTA Decisions - 2024 vs 2025
- 2025 Sales
- 2024 vs. 2025 Sales
- 2024 vs. 2025 Company Market Capitalization
- Key Findings
- Appendix
- Abbreviations
- Methodology
- About the Authors
- About the Analyst
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- GSK plc
- Bristol-Myers Squibb Co
- AstraZeneca Plc
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Merck & Co Inc
- Johnson & Johnson
- Sanofi
- Pfizer Inc
- AbbVie Inc
- Eli Lilly and Co
- Eisai Co Ltd
- Anavex Life Sciences Corp
- Vertex Pharmaceuticals Inc
- Madrigal Pharmaceuticals Inc
- Astellas Pharma Inc
- Bayer AG
- Biogen Inc
- Mitsubishi Tanabe Pharma Corp
- Takeda Pharmaceutical Co Ltd
- UCB SA
- Amgen Inc
- Novo Nordisk AS
- Lee's Pharmaceutical Holdings Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Ipsen SA
- Daiichi Sankyo
- Regeneron
- Vanda Pharma,Basilea Pharma
- Dachii Sankyo
- Merck & Co
